ARTICLE | Clinical News

Decapeptyl triptorelin pamoate regulatory update

November 23, 2009 8:00 AM UTC

Ipsen said France approved an MAA for a 6-month formulation of 22.5 mg Decapeptyl triptorelin pamoate to treat locally advanced or metastatic prostate cancer. The company plans to launch the product in France next half. Ipsen said it has not heard back from the eight other European countries where the application is under review, including Germany, which is acting as the reference state under the decentralized procedure (see BioCentury, Oct. 19). ...